In addition, TREM-1 + TAMs also respond to hypoxic conditions and tumor metabolites through the ERK/NF-κβ pathway, resulting in an increase in CCR6 + Foxp3 + Tregs, which promotes tumor immunosuppression and creates resistance to PD-L1-targeted therapies [142, 143]. The gene discussed is CCR6; the disease is neoplasm.